Study #2020-0075
PIONEER-Panc: Phase II Investigations of New and Emerging Therapies for Pancreatic Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Fluorouracil, Irinotecan, Leucovorin, Oxaliplatin, Cisplatin, Gemcitabine, Nab-paclitaxel
Description
This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease. Each stage group will have a defined standard of care chemotherapy regimen for a control arm, serving as a basis of comparison. Each group may have one or more experimental arms. Experimental arms may be added to the platform over time, and the effects of the experimental treatments will be tested against the controls for each group.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Study phase:
Phase II
Physician name:
Eugene Koay
Department:
Radiation Oncology
For general questions about clinical trials:
1-833-676-1615
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.